Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer

Chemotherapy‐induced myelosuppression is an acute, dose‐limiting toxicity of chemotherapy regimens used in the treatment of extensive‐stage small cell lung cancer (ES‐SCLC). Trilaciclib protects haematopoietic stem and progenitor cells from chemotherapy‐induced damage (myeloprotection). To assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Dómine Gómez, Manuel, Csőszi, Tibor, Jaal, Jana, Kudaba, Iveta, Nikolov, Krasimir, Radosavljevic, Davorin, Xiao, Jie, Horton, Janet K., Malik, Rajesh K., Subramanian, Janakiraman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457063/
https://www.ncbi.nlm.nih.gov/pubmed/34109630
http://dx.doi.org/10.1002/ijc.33705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457063/
https://www.ncbi.nlm.nih.gov/pubmed/34109630
http://dx.doi.org/10.1002/ijc.33705

Ejemplares similares